

# Peter E Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6226961/publications.pdf>

Version: 2024-02-01

256  
papers

10,112  
citations

29994

54  
h-index

45213

90  
g-index

264  
all docs

264  
docs citations

264  
times ranked

11439  
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial and Socioeconomic Disparities in MRI-Fusion Biopsy Utilization to Assess for Prostate Cancer. <i>Urology</i> , 2022, 163, 156-163.	0.5	1
2	GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. <i>International Journal of Urology</i> , 2022, 29, 641-645.	0.5	4
3	Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 102.	0.4	3
4	Safety of decreasing ureteral stent duration following radical cystectomy. <i>World Journal of Urology</i> , 2021, 39, 473-479.	1.2	6
5	Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2021, 20, 398-409.	1.9	17
6	Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. <i>Human Pathology</i> , 2021, 107, 96-103.	1.1	6
7	Genomic analysis of response to bacillus Calmette-Guèrin (BCG) treatment in high-grade stage 1 bladder cancer patients. <i>Translational Andrology and Urology</i> , 2021, 10, 0-0.	0.6	3
8	Clinical Utility of Postneoadjuvant Chemotherapy Computerized Tomography for Muscle Invasive Urothelial Bladder Cancer. <i>Urology Practice</i> , 2021, 8, 88-93.	0.2	0
9	Demographic and Socioeconomic Factors Associated with Urinary Stone Disease Management in a Large Urban US Population. <i>Urology</i> , 2021, 153, 93-100.	0.5	3
10	Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study. <i>Journal of Urology</i> , 2021, 206, 270-278.	0.2	5
11	Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 420.	0.3	2
12	Increased nuclear factor I/B expression in prostate cancer correlates with AR expression. <i>Prostate</i> , 2020, 80, 1058-1070.	1.2	7
13	Safety and effectiveness of percutaneous renal cryoablation with conscious sedation. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 163-168.	0.7	2
14	EDITORIAL COMMENT. <i>Urology</i> , 2020, 142, 131-132.	0.5	0
15	Epidemiology and survival outcome of adult kidney, bladder, and prostate rhabdomyosarcoma: A SEER database analysis. <i>Rare Tumors</i> , 2020, 12, 203636132097740.	0.3	6
16	Transversus Abdominis Plane (TAP) Block as a Key Component of a Dedicated Enhanced Recovery after Surgery Program for Nephrectomy Patients. <i>Journal of the American College of Surgeons</i> , 2020, 231, S339-S340.	0.2	0
17	Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort. <i>Bladder Cancer</i> , 2020, 6, 83-90.	0.2	2
18	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	0.9	32

#	ARTICLE	IF	CITATIONS
19	Implementation of a Dedicated Enhanced Recovery after Surgery (ERAS) Program for Radical Cystectomy Patients is Associated With Decreased Postoperative Inpatient Opioid Usage and Pain Scores. <i>Urology</i> , 2020, 143, 186-193.	0.5	5
20	Management changes for patients with endocrine-related cancers in the COVID-19 pandemic. <i>Endocrine-Related Cancer</i> , 2020, 27, R357-R374.	1.6	22
21	Comparison of venous thromboembolic complications following urological surgery between patients with or without cancer. <i>Turkish Journal of Urology</i> , 2020, 46, 277-281.	1.3	1
22	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUDâ€“SIU joint consultation on bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 3-13.	1.2	42
23	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	1.4	27
24	High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 900-906.	0.8	5
25	Opioid Epidemic and Urology: Effects of Preoperative Opioid Usage on Postoperative Clinical Outcomes in Radical Cystectomy Patients. <i>Journal of the American College of Surgeons</i> , 2019, 229, S318.	0.2	0
26	Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 785-790.	2.0	38
27	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€”A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002724.	3.9	59
28	Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 299.e19-299.e25.	0.8	30
29	MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. <i>Prostate</i> , 2018, 78, 616-622.	1.2	13
30	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). <i>Research and Reports in Urology</i> , 2018, Volume 10, 181-187.	0.6	2
31	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 1317-1318.	0.2	0
32	Core Needle Biopsy and Fine Needle Aspiration Alone or in Combination: Diagnostic Accuracy and Impact on Management of Renal Masses. <i>Journal of Urology</i> , 2017, 197, 1396-1402.	0.2	10
33	Functional <i>KRAS</i> mutations and a potential role for PI3K/AKT activation in Wilms tumors. <i>Molecular Oncology</i> , 2017, 11, 405-421.	2.1	22
34	TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 286-293.	0.8	16
35	New developments in the management of nonmuscle invasive bladder cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 179-183.	1.1	2
36	On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 98-106.	1.9	30

#	ARTICLE	IF	CITATIONS
37	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
38	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
39	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	0.9	39
40	Blocking TGF- $\beta$ 2 and $\beta$ 2-Catenin Epithelial Crosstalk Exacerbates CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3490-3503.	3.0	50
41	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	57
42	Pharmacologic Inhibition of $\beta$ 2-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. <i>Oncology Research</i> , 2017, 25, 1653-1664.	0.6	10
43	Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. <i>Oncotarget</i> , 2017, 8, 722-741.	0.8	22
44	Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. <i>PLoS ONE</i> , 2016, 11, e0156918.	1.1	43
45	Natural biology and management of nonmuscle invasive bladder cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 210-215.	1.1	3
46	NF- $\kappa$ B and androgen receptor variant expression correlate with human BPH progression. <i>Prostate</i> , 2016, 76, 491-511.	1.2	49
47	Renal cell cancer histological subtype distribution differs by race and sex. <i>BJU International</i> , 2016, 117, 260-265.	1.3	115
48	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
49	Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 29-44.	1.7	24
50	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. <i>Journal of Health Communication</i> , 2016, 21, 99-104.	1.2	55
51	MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 294-302.	0.4	12
52	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3346-3348.	0.8	6
53	Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. <i>Nature Communications</i> , 2016, 7, 11240.	5.8	91
54	NF- $\kappa$ B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. <i>Prostate</i> , 2016, 76, 1004-1018.	1.2	22

#	ARTICLE	IF	CITATIONS
55	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. <i>Journal of Urology</i> , 2016, 196, 1030-1035.	0.2	23
56	Trends in kidney cancer among the elderly in Denmark, 1980â€“2012. <i>Acta OncolÃ³gica</i> , 2016, 55, 79-84.	0.8	14
57	Long-term Use of Statins and Risk of Renal Cell Carcinoma: A Population-based Caseâ€“Control Study. <i>European Urology</i> , 2016, 69, 877-882.	0.9	18
58	Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 258.e1-258.e6.	0.8	14
59	Follow-up imaging in the first two years after nephrectomy for T1 RCC: Over-use or necessary care?. <i>Journal of Clinical Urology</i> , 2016, 9, 105-113.	0.1	0
60	MAGI-2 in prostate cancer: an immunohistochemical study. <i>Human Pathology</i> , 2016, 52, 83-91.	1.1	18
61	Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. <i>Endocrinology</i> , 2016, 157, 1094-1109.	1.4	27
62	Short term complications from transurethral resection of bladder tumor. <i>Canadian Journal of Urology</i> , 2016, 23, 8198-203.	0.0	28
63	Genetic and chromosomal alterations in K enyan W ilms T umor. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 702-715.	1.5	22
64	Urothelial carcinoma with squamous differentiation: Response to chemotherapy and radiation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 434-436.	0.8	9
65	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. <i>BJU International</i> , 2015, 116, 351-357.	1.3	29
66	Toward Personalized Guidelines in Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1458-1460.	2.3	1
67	Management of noninvasive bladder cancers. <i>Current Opinion in Oncology</i> , 2015, 27, 185-190.	1.1	13
68	Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. <i>Bladder Cancer</i> , 2015, 1, 143-150.	0.2	3
69	Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. <i>American Journal of Pathology</i> , 2015, 185, 1385-1395.	1.9	60
70	A Murine Model of K-RAS and Î²-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor. <i>Journal of Urology</i> , 2015, 194, 1762-1770.	0.2	15
71	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 21.e11-21.e17.	0.8	25
72	Lack of P16 <sup>ink4a</sup> Over Expression in Penile Squamous Cell Carcinoma is Associated with Recurrence after Lymph Node Dissection. <i>Journal of Urology</i> , 2015, 193, 519-525.	0.2	20

#	ARTICLE	IF	CITATIONS
73	Incidence and predictors of understaging in patients with clinical $\leq T1$ urothelial carcinoma undergoing radical cystectomy. <i>BJU International</i> , 2014, 113, 894-899.	1.3	67
74	Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. <i>Prostate</i> , 2014, 74, 669-679.	1.2	37
75	NF- $\kappa$ B Gene Signature Predicts Prostate Cancer Progression. <i>Cancer Research</i> , 2014, 74, 2763-2772.	0.4	99
76	Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 512-516.	0.9	5
77	Developments and controversies in the management of noninvasive bladder cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 299-304.	1.1	1
78	F2-Isoprostanes as a Biomarker of Oxidative Stress in the Mouse Bladder. <i>Journal of Urology</i> , 2014, 191, 1597-1601.	0.2	13
79	Biochemical Recurrence-free Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2014, 83, 1309-1315.	0.5	27
80	Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 45.e11-45.e15.	0.8	16
81	Impact of Complications and Hospital-Free Days on Health Related Quality of Life 1 Year after Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 1360-1364.	0.2	19
82	Association between physical activity, lower urinary tract symptoms ( $\leq$ LUTS $\leq$ ) and prostate volume. <i>BJU International</i> , 2013, 111, 122-128.	1.3	29
83	When urothelial differentiation pathways go wrong: Implications for bladder cancer development and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 802-811.	0.8	33
84	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826.	0.8	7
85	Imaging the Clear Cell Renal Cell Carcinoma Proteome. <i>Journal of Urology</i> , 2013, 189, 1097-1103.	0.2	40
86	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	0.9	225
87	Ureteroenteric Anastomotic Strictures After Radical Cystectomy—Does Operative Approach Matter?. <i>Journal of Urology</i> , 2013, 189, 541-547.	0.2	113
88	Anatomic Basis for Lymph Node Counts as Measure of Lymph Node Dissection Extent: A Cadaveric Study. <i>Urology</i> , 2013, 81, 358-363.	0.5	43
89	Salvage Robotic Assisted Laparoscopic Radical Prostatectomy: A Single Institution, 5-Year Experience. <i>Journal of Urology</i> , 2013, 189, 507-513.	0.2	70
90	Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 295-304.	0.8	5

#	ARTICLE	IF	CITATIONS
91	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 871-877.	0.8	86
92	Management of superficial and muscle-invasive urothelial cancers of the bladder. <i>Current Opinion in Oncology</i> , 2013, 25, 281-288.	1.1	36
93	Current Concepts in Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 617-624.	2.3	22
94	Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 594-615.	2.3	149
95	Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 446-475.	2.3	309
96	Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. <i>Current Opinion in Oncology</i> , 2012, 24, 278-283.	1.1	7
97	ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. <i>BJU International</i> , 2012, 110, E641-6.	1.3	47
98	National Trends in the Use of Partial Nephrectomy: A Rising Tide That Has Not Lifted All Boats. <i>Journal of Urology</i> , 2012, 187, 816-821.	0.2	109
99	Recovery of Urinary Function After Radical Prostatectomy: Identification of Trajectory Cluster Groups. <i>Journal of Urology</i> , 2012, 187, 1346-1351.	0.2	15
100	977 ABO BLOOD TYPE IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
101	127 VOLUME-OUTCOMES IN CYSTECTOMY: IS IT THE SURGEON OR THE SETTING?. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
102	381 SALVAGE ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY A SINGLE INSTITUTION FIVE-YEAR EXPERIENCE. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
103	434 NOVEL RENAL CELL CARCINOMA BIOMARKER IDENTIFICATION FROM URINARY EXOSOMES. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
104	441 IDENTIFICATION OF A MULTIPLE PEPTIDE SIGNATURE BY IMAGING MASS SPECTROMETRY WHICH ACCURATELY PREDICTS MORTALITY IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
105	527 CHANGING UTILIZATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPIES FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER PUBLICATION OF LANDMARK MANUSCRIPTS. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
106	Voiding Function in Women with Orthotopic Neobladder Urinary Diversion. <i>Journal of Urology</i> , 2012, 188, 200-204.	0.2	61
107	1803 A PROGNOSTIC MODEL FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
108	1586 BLOOD LOSS ASSOCIATED WITH RADICAL CYSTECTOMY A PROSPECTIVE RANDOMIZED STUDY COMPARING IMPACT LIGASURE VERSUS STAPLING DEVICE. <i>Journal of Urology</i> , 2012, 187, .	0.2	1

#	ARTICLE	IF	CITATIONS
109	1226 PERIOPERATIVE COST COMPARISON OF ROBOTIC AND OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
110	1426 CONTEMPORARY MANAGEMENT OF SMALL RENAL MASSES: PARTIAL NEPHRECTOMY IS ASSOCIATED EXCLUSIVELY WITH TUMOR ANATOMIC COMPLEXITY. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
111	1757 USE OF PELVIC LYMPHADENECTOMY IN RADICAL CYSTECTOMY FOR BLADDER CANCER: 10-YEAR EXPERIENCE AT A SINGLE INSTITUTION. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
112	1185 RECOVERY OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
113	1900 WORTH A SECOND LOOK: RATES OF UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY AFTER RESTAGING TURBT FOR PERSISTENT T1 UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
114	Volume Outcomes of Cystectomy—Is it the Surgeon or the Setting?. <i>Journal of Urology</i> , 2012, 188, 2139-2144.	0.2	57
115	1763 TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF PATIENTS 50 YEARS OLD AND YOUNGER UNDERGOING DEFINITIVE TREATMENT FOR BLADDER UROTHELIAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
116	Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. <i>Urology</i> , 2012, 80, 632-640.	0.5	44
117	1064 A NOVEL SIMULATION MODEL OF NON-MUSCLE INVASIVE BLADDER CANCER A PLATFORM FOR A VIRTUAL RANDOMIZED TRIAL OF CONSERVATIVE THERAPY VS CYSTECTOMY IN BCG REFRACTORY PATIENTS. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
118	Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation. <i>PLoS ONE</i> , 2012, 7, e36669.	1.1	81
119	Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. <i>BJU International</i> , 2012, 109, 1607-1613.	1.3	28
120	Shed alcam as a biomarker for urogenital cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 50-50.	0.8	0
121	1895 PELVIC LYMPH NODE DISSECTION FOR BLADDER CANCER: AN AUTOPSY STUDY. <i>Journal of Urology</i> , 2011, 185, .	0.2	1
122	Determining Factors for Hospital Discharge Status After Radical Cystectomy in a Large Contemporary Cohort. <i>Journal of Urology</i> , 2011, 185, 85-89.	0.2	59
123	Effect of Preoperative Nutritional Deficiency on Mortality After Radical Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2011, 185, 90-96.	0.2	212
124	Î²-Catenin and K-RAS Synergize to Form Primitive Renal Epithelial Tumors with Features of Epithelial Wilms' Tumors. <i>American Journal of Pathology</i> , 2011, 179, 3045-3055.	1.9	29
125	PPARÎ³: A molecular link between systemic metabolic disease and benign prostate hyperplasia. <i>Differentiation</i> , 2011, 82, 220-236.	1.0	41
126	Assessing the Surgical Skills of Urology Residents After Preurology General Surgery Training: The Surgical Skills Learning Needs of New Urology Residents. <i>Journal of Surgical Education</i> , 2011, 68, 341-346.	1.2	7



#	ARTICLE	IF	CITATIONS
127	Urinary Collecting System Invasion Is a Predictor for Overall and Disease-specific Survival in Locally Invasive Renal Cell Carcinoma. <i>Urology</i> , 2011, 78, 99-104.	0.5	21
128	Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy. <i>Journal of Urology</i> , 2011, 186, 829-834.	0.2	97
129	Prostate Size as a Predictor of Gleason Score Upgrading in Patients With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 2221-2227.	0.2	53
130	Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. <i>PLoS ONE</i> , 2011, 6, e22486.	1.1	80
131	Bladder cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 275-282.	1.1	40
132	Men's Knowledge and Beliefs About Colorectal Cancer and 3 Screenings: Education, Race, and Screening Status. <i>American Journal of Health Behavior</i> , 2011, 35, 525-34.	0.6	29
133	Comparison and assessment of semi-automatic image segmentation in computed tomography scans for image-guided kidney surgery. <i>Medical Physics</i> , 2011, 38, 6265-6274.	1.6	1
134	Detection of Tumor Cells in the Bone Offers Independent Prognostic Value in Bladder Cancer Patients: The Clinical and Basic Science Perspective. <i>European Urology</i> , 2011, 60, 239-240.	0.9	0
135	Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 923-928.	0.9	146
136	Reply to Sabine Brookman-May, Maximilian Burger, Wolf F. Wieland, and Matthias May's Letter to the Editor re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>Eur Urol</i> 2011;59:923-8. <i>European Urology</i> , 2011, 60, e47.	0.9	0
137	Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: A tale of two methods. <i>World Journal of Urology</i> , 2011, 29, 15-20.	1.2	16
138	Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 194-201.	157.7	148
139	Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. <i>BJU International</i> , 2010, 106, 1036-1040.	1.3	68
140	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. <i>Biologics: Targets and Therapy</i> , 2010, 4, 187.	3.0	2
141	Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. <i>Circulation</i> , 2010, 121, 833-840.	1.6	312
142	Bladder cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 242-249.	1.1	32
143	Early and Late Perioperative Outcomes Following Radical Cystectomy: 90-Day Readmissions, Morbidity and Mortality in a Contemporary Series. <i>Journal of Urology</i> , 2010, 184, 1296-1300.	0.2	226
144	Comparative Analysis of Whole Mount Processing and Systematic Sampling of Radical Prostatectomy Specimens: Pathological Outcomes and Risk of Biochemical Recurrence. <i>Journal of Urology</i> , 2010, 184, 1334-1340.	0.2	19

#	ARTICLE	IF	CITATIONS
145	TRAIL and Interferon- $\gamma$ Act Synergistically to Induce Renal Cell Carcinoma Apoptosis. Journal of Urology, 2010, 184, 1166-1174.	0.2	13
146	Smaller Prostate Size Predicts High Grade Prostate Cancer at Final Pathology. Journal of Urology, 2010, 184, 930-937.	0.2	49
147	A Simple, Effective Method to Create Laparoscopic Renal Protective Hypothermia With Cold Saline Surface Irrigation: Clinical Application and Assessment. Journal of Urology, 2010, 184, 1861-1866.	0.2	26
148	Preoperative Hydronephrosis Predicts Extravesical and Node Positive Disease in Patients Undergoing Cystectomy for Bladder Cancer. Journal of Urology, 2010, 183, 1732-1737.	0.2	50
149	Infant communicating hydroceles“do they need immediate repair or might some clinically resolve?. Journal of Pediatric Surgery, 2010, 45, 590-593.	0.8	39
150	Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996-2007: A Danish Population-based Cohort Study. Urology, 2010, 75, 393-398.	0.5	31
151	Intraprocedural Registration for Image-Guided Kidney Surgery. IEEE/ASME Transactions on Mechatronics, 2010, 15, 847-852.	3.7	14
152	Robotic Assisted Laparoscopic Prostatectomy Versus Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer: Comparison of Short-Term Biochemical Recurrence-Free Survival. Journal of Urology, 2010, 183, 990-996.	0.2	131
153	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2009, 9, 821-830.	1.1	19
154	Masculinity and the Body: How African American and White Men Experience Cancer Screening Exams Involving the Rectum. American Journal of Men's Health, 2009, 3, 300-309.	0.7	51
155	The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney International, 2009, 76, 939-945.	2.6	100
156	Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis, 2009, 30, 1358-1362.	1.3	53
157	Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. Cancer, 2009, 115, 770-775.	2.0	27
158	Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base. Cancer, 2009, 115, 2447-2452.	2.0	22
159	Prognostic factors in T3b renal cell carcinoma. World Journal of Urology, 2009, 27, 75-79.	1.2	20
160	Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU International, 2009, 104, 934-937.	1.3	14
161	Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU International, 2009, 104, 1091-1097.	1.3	18
162	Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48â€f000 patients. BJU International, 2009, 104, 1442-1445.	1.3	15

#	ARTICLE	IF	CITATIONS
163	Open renal biopsy: comorbidities and complications in a contemporary series. BJU International, 2009, 106, 102-106.	1.3	8
164	Intake of Plant Foods and Associated Nutrients in Prostate Cancer Risk. Nutrition and Cancer, 2009, 61, 216-224.	0.9	57
165	Sigmoidâ€“Urachalâ€“Cutaneous Fistula in an Adult Male. Urology, 2009, 73, 444.e5-444.e7.	0.5	12
166	RELATIONSHIP BETWEEN PROSTATE VOLUME AND PATHOLOGIC GRADE OF PROSTATE CANCER. Journal of Urology, 2009, 181, 710.	0.2	0
167	Comparison of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma: Analysis of Patient Outcomes in Organ Confined Bladder Cancer. Journal of Urology, 2009, 181, 540-546.	0.2	20
168	RELATIONSHIP OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY WITH MEDICAL COMORBIDITIES AND GLOBAL QUALITY OF LIFE PARAMETERS. Journal of Urology, 2009, 181, 89-89.	0.2	0
169	IDENTIFICATION OF DISTINCT OUTCOMES CLUSTERS FOR URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 4-4.	0.2	0
170	IMPACT OF POSITIVE APICAL SURGICAL MARGINS (SM) ON THE LIKELIHOOD OF BIOCHEMICAL RECURRENCE (BCR) AFTER PROSTATECTOMY. Journal of Urology, 2009, 181, 668-669.	0.2	0
171	Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center. Journal of Urology, 2009, 182, 2369-2375.	0.2	43
172	Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy. Journal of Urology, 2009, 182, 2695-2701.	0.2	48
173	PROGNOSTIC FACTORS IN T3B RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 494-495.	0.2	0
174	COMPARISON OF 3-YEAR CANCER CONTROL OUTCOMES IN ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY (RALP) VERSUS RADICAL RETROPUbic PROSTATECTOMY (RRP) FOR PROSTATE CANCER. Journal of Urology, 2009, 181, 455-455.	0.2	0
175	Pathological Stage T2 Subgroups to Predict Biochemical Recurrence After Prostatectomy. Journal of Urology, 2009, 182, 2291-2295.	0.2	44
176	Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 8-39.	2.3	58
177	Bladder cancer. Current Opinion in Oncology, 2009, 21, 272-277.	1.1	48
178	Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Ethnicity and Disease, 2009, 19, 199-203.	1.0	47
179	Neovesicalâ€“urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU International, 2008, 101, 219-222.	1.3	12
180	The von Hippel-Lindau gene. Cancer, 2008, 113, 1768-1778.	2.0	39

#	ARTICLE	IF	CITATIONS
181	Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. <i>Brachytherapy</i> , 2008, 7, 286-289.	0.2	4
182	Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. <i>BJU International</i> , 2008, 101, 1140-1144.	1.3	36
183	RADICAL NEPHRECTOMY SURGICAL OUTCOMES IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE AND GEOGRAPHIC LOCATION ON 40,000 PATIENTS. <i>Journal of Urology</i> , 2008, 179, 164-164.	0.2	0
184	Waiting Time From Initial Urological Consultation to Nephrectomy for Renal Cell Carcinoma—Does it Affect Survival?. <i>Journal of Urology</i> , 2008, 179, 2152-2157.	0.2	32
185	SURVIVAL OUTCOMES IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2008, 179, 380-380.	0.2	0
186	RISK FACTORS FOR UROTHELIAL CARCINOMA OF THE PROSTATE IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER. <i>Journal of Urology</i> , 2008, 179, 532-533.	0.2	0
187	WAITING TIME FROM DIAGNOSIS TO NEPHRECTOMY FOR RENAL CELL CARCINOMA: DOES IT AFFECT SURVIVAL?. <i>Journal of Urology</i> , 2008, 179, 415-416.	0.2	1
188	UTILIZATION OF SYSTEMIC THERAPY IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2008, 179, 330-331.	0.2	0
189	Contemporary Open Radical Cystectomy: Analysis of Perioperative Outcomes. <i>Journal of Urology</i> , 2008, 179, 1313-1318.	0.2	193
190	A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T3a VERSUS T3b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES. <i>Journal of Urology</i> , 2008, 179, 546-546.	0.2	1
191	A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T2a VERSUS T2b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES IN ORGAN CONFINED BLADDER CANCER. <i>Journal of Urology</i> , 2008, 179, 579-579.	0.2	0
192	THE IMPACT OF COMORBIDITY ON SURVIVAL OF INVASIVE BLADDER CANCER PATIENTS, 1995-2004; A DANISH POPULATION-BASED COHORT STUDY. <i>Journal of Urology</i> , 2008, 179, 532-532.	0.2	0
193	Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy. <i>Clinical Cancer Research</i> , 2008, 14, 7790-7797.	3.2	51
194	Bladder cancer. <i>Current Opinion in Oncology</i> , 2008, 20, 307-314.	1.1	55
195	Renal Peripheral Neuroectodermal Tumor Presenting at Age 78: Case Report. <i>Scientific World Journal</i> , The, 2008, 8, 830-834.	0.8	7
196	Microwave Ablation of Renal Parenchymal Tumors Before Nephrectomy: Phase I Study. <i>American Journal of Roentgenology</i> , 2007, 188, 1212-1214.	1.0	75
197	CT-Guided Biopsy for the Diagnosis of Renal Tumors Before Treatment with Percutaneous Ablation. <i>American Journal of Roentgenology</i> , 2007, 188, 1500-1505.	1.0	59
198	Oncologic Efficacy of CT-Guided Percutaneous Radiofrequency Ablation of Renal Cell Carcinomas. <i>American Journal of Roentgenology</i> , 2007, 189, 429-436.	1.0	282

#	ARTICLE	IF	CITATIONS
199	Recent advances in targeted therapy for renal cell carcinoma. <i>Current Opinion in Urology</i> , 2007, 17, 331-336.	0.9	18
200	Bladder cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 241-247.	1.1	18
201	A Simple Model Predicts Freedom From Biochemical Recurrence After Low-Dose Rate Prostate Brachytherapy Alone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 199-204.	0.6	4
202	Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 196-200.	0.8	18
203	Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding. <i>Journal of Biological Chemistry</i> , 2007, 282, 28189-28194.	1.6	70
204	Assessing Retroperitoneal Lymphadenectomy Experience in United States Urological Residency Programs. <i>Journal of Urology</i> , 2007, 178, 500-503.	0.2	17
205	Interactions of cytokine gene polymorphisms in prostate cancer risk. <i>Carcinogenesis</i> , 2007, 29, 573-578.	1.3	59
206	Association of Procedure Volume With Radical Cystectomy Outcomes in a Nationwide Database. <i>Journal of Urology</i> , 2007, 178, 1418-1422.	0.2	106
207	A Comparison of the Incidence and Location of Positive Surgical Margins in Robotic Assisted Laparoscopic Radical Prostatectomy and Open Retropubic Radical Prostatectomy. <i>Journal of Urology</i> , 2007, 178, 2385-2390.	0.2	255
208	Hope and Challenges in the Management of Advanced Renal Cell Carcinoma. <i>Scientific World Journal</i> , The, 2007, 7, 869-869.	0.8	0
209	Upper tract transitional cell carcinoma: Finding a way forward. <i>Cancer</i> , 2007, 110, 1648-1649.	2.0	0
210	178: Examining Contemporary Urinary Diversion: A Review of Changing Practice Patterns Diversion Selectivity. <i>Journal of Urology</i> , 2007, 177, 60-60.	0.2	1
211	1648: The Influence of Histopathologic Method on Prostatic Carcinoma Incidence and Gleason Grade in Cystoprostatectomy Specimens. <i>Journal of Urology</i> , 2007, 177, 546-547.	0.2	0
212	574: Prospective Assessment of Health Related Quality of Life (HRQOL) at One Year Following Radical Cystectomy and Urinary Diversion. <i>Journal of Urology</i> , 2007, 177, 191-192.	0.2	0
213	Complementary and Alternative Medicine for Advanced Prostate Cancer. <i>Urologic Clinics of North America</i> , 2006, 33, 237-246.	0.8	29
214	Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. <i>Urology</i> , 2006, 67, 349-353.	0.5	23
215	Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. <i>Urology</i> , 2006, 67, 1257-1261.	0.5	90
216	Bladder cancer. <i>Current Opinion in Oncology</i> , 2006, 18, 277-283.	1.1	13

#	ARTICLE	IF	CITATIONS
217	Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. <i>Cancer</i> , 2006, 107, 1093-1100.	2.0	15
218	DNA damage levels in prostate cancer cases and controls. <i>Carcinogenesis</i> , 2006, 27, 1187-1193.	1.3	45
219	Bladder cancer. <i>Current Opinion in Oncology</i> , 2005, 17, 275-280.	1.1	30
220	Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V100 superior to D90?. <i>Brachytherapy</i> , 2005, 4, 252-258.	0.2	51
221	Radical cystectomy in the elderly. <i>Cancer</i> , 2005, 103, 546-552.	2.0	61
222	Radical cystectomy in the elderly. <i>Cancer</i> , 2005, 104, 36-43.	2.0	193
223	A Rare Case of an Extra-Adrenal Myelolipoma Arising in the Renal Sinus: A Case Report and Review of the Literature. <i>Scientific World Journal, The</i> , 2005, 5, 109-117.	0.8	5
224	Recent advances in the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1023-1030.	1.1	2
225	Contemporary Management of the Urethra in Patients After Radical Cystectomy for Bladder Cancer. <i>Urologic Clinics of North America</i> , 2005, 32, 199-206.	0.8	18
226	URETHRAL TUMOR RECURRENCE FOLLOWING CYSTECTOMY AND URINARY DIVERSION: CLINICAL AND PATHOLOGICAL CHARACTERISTICS IN 768 MALE PATIENTS. <i>Journal of Urology</i> , 2005, 173, 1163-1168.	0.2	176
227	Inflammatory myofibroblastic tumor associated with renal cell carcinoma. <i>Urology</i> , 2005, 66, 880.e7-880.e9.	0.5	18
228	Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 328-332.	0.8	4
229	1014: Prospective Dose-Escalation Trial of Lycopene in Men with Recurrent Prostate Cancer Following Definitive Local Therapy. <i>Journal of Urology</i> , 2005, 173, 275-275.	0.2	3
230	Percutaneous CT-Guided Radiofrequency Ablation of Renal Neoplasms: Factors Influencing Success. <i>American Journal of Roentgenology</i> , 2004, 183, 201-207.	1.0	182
231	The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function. <i>Cancer Research</i> , 2004, 64, 6344-6348.	0.4	159
232	Radiofrequency ablation of renal tumors. <i>Current Urology Reports</i> , 2004, 5, 39-44.	1.0	6
233	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 640-645.	0.2	61
234	THE MANAGEMENT OF URETHRAL TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY FOR INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2004, 172, 1342-1347.	0.2	86

#	ARTICLE	IF	CITATIONS
235	Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. <i>Urology</i> , 2004, 63, 1061-1065.	0.5	24
236	Utility of frozen section analysis of resection margins during partial nephrectomy. <i>Urology</i> , 2004, 64, 31-34.	0.5	56
237	Bladder cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 257-262.	1.1	14
238	Endourologic Management of Upper Tract Transitional Cell Carcinoma. <i>Scientific World Journal</i> , The, 2004, 4, 62-75.	0.8	6
239	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , 2003, 98, 955-961.	2.0	49
240	The Androgen Receptor CAG Repeat and Prostate Cancer Risk. , 2003, 81, 255-266.		17
241	Bladder cancer. <i>Current Opinion in Oncology</i> , 2003, 15, 227-233.	1.1	45
242	Prostate Cancer and Bone Metastases: Medical Treatment. <i>Clinical Orthopaedics and Related Research</i> , 2003, 415, S148-S157.	0.7	22
243	Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. <i>Molecular Cancer Research</i> , 2003, 1, 385-92.	1.5	50
244	Angiomyolipoma with vena caval extension. <i>Urology</i> , 2002, 60, 695-696.	0.5	19
245	Urinary diversion after radical cystectomy. <i>Current Treatment Options in Oncology</i> , 2002, 3, 389-402.	1.3	12
246	Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2001, 57, 281-285.	0.5	103
247	Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. <i>Urology</i> , 2001, 57, 252-256.	0.5	134
248	EXOPHYTIC NONINVASIVE GROWTH PATTERN OF RENAL ANGIOMYOLIPOMAS: : IMPLICATIONS FOR NEPHRON SPARING SURGERY. <i>Journal of Urology</i> , 2001, 165, 513-514.	0.2	7
249	Intermediate-Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience. <i>Prostate Journal</i> , 2001, 3, 118-125.	0.2	11
250	Alterations in NF- $\kappa$ B Activation in T Lymphocytes of Patients With Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 1999, 91, 718-721.	3.0	78
251	13-YEAR EXPERIENCE WITH PERCUTANEOUS MANAGEMENT OF UPPER TRACT TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 1999, 161, 772-776.	0.2	115
252	Renal cell carcinoma-derived gangliosides suppress nuclear factor- $\kappa$ B activation in T cells. <i>Journal of Clinical Investigation</i> , 1999, 104, 769-776.	3.9	110

#	ARTICLE	IF	CITATIONS
253	Surgery for invasive bladder tumors: technique and outcome. Current Opinion in Urology, 1999, 9, 413-418.	0.9	0
254	Impaired Activation of NF $\kappa$ B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, I $\kappa$ B $\beta$ . Blood, 1998, 92, 1334-1341.	0.6	55
255	Impaired Activation of NF $\kappa$ B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, I $\kappa$ B $\beta$ . Blood, 1998, 92, 1334-1341.	0.6	3
256	Original Articles: Testis Cancer: A Review of Scrotal Violation in Testicular Cancer: Is Adjuvant Local Therapy Necessary?. Journal of Urology, 1995, 153, 981-985.	0.2	87